PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Revenue of PolyPeptide Group AG (PPGN.SW)
Revenue in 2023 (TTM): $362.75 M
According to PolyPeptide Group AG's latest financial reports the company's current revenue (TTM) is $362.75 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PolyPeptide Group AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $362.75 M | $5.26 M | $-13,937,199 | $-65,947,218 | $-58,244,336 |
| 2022 | $318.14 M | $58.87 M | $40.45 M | $8.57 M | $8.79 M |
| 2021 | $319.44 M | $112.89 M | $94.38 M | $67.76 M | $53.51 M |
| 2020 | $253.97 M | $82.87 M | $66.29 M | $42.67 M | $35.48 M |
| 2019 | $229.41 M | $81.04 M | $55.8 M | $34.23 M | $29.14 M |
| 2018 | $203.33 M | $70.34 M | $48.22 M | $33.35 M | $26.97 M |